Key statistics dashboard for Alzamend Neuro Inc (ALZN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a meth...
Stock Data
| Price | $1.83 |
| Market Cap | $7M |
| Enterprise Value | -$628770 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.80 |
| Price / Book | 1.41 |
| P/S | 0.00 |
| EV/EBITDA | 0.07 |
| EV/Sales | 0.00 |
| EV/FCF | 0.09 |
| P/FCF | -1.02 |
| Earnings Yield | -110.99% |
| FCF Yield | -98.29% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -277.88% |
| Return on Assets | -106.49% |
| Return on Invested Capital | -156.69% |
| Return on Capital Employed | -156.69% |
Financial Health
| Current Ratio | 3.01 |
| Quick Ratio | 3.01 |
| Cash Ratio | 2.77 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Net Debt / EBITDA | 0.83 |
| Interest Coverage | 818.59 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -57.29 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 1.30 |
| Cash per share | 1.70 |
| FCF per share | -1.53 |
| Tangible Book Value per share | 1.30 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 2 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 2 |
| Avg rating (1-5) | 1.00 |
Related companies: ACXP · ADIL · APRE · BCDA · CDIO · CELZ · HCWB
Explore sector: Healthcare · Biotechnology
More sections of ALZN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks